Syngene International Ltd
Syngene International Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Get Syngene International Ltd's next results in your feed
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Syngene expects the single large molecule product impact to continue through FY26 Q4 and into a couple of quarters in FY27 before it plays out. Syngene expects the single large molecule product impact to continue into FY27 but to play out over the next few quarters.
From Syngene International Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Syngene expects the single large molecule product impact to continue through FY26 Q4 and into a couple of quarters in FY27 before it plays out.
- Excluding this one-off headwind, the rest of the business is growing steadily at high single-digit to low double-digit rates (constant currency).
- Growth is broad-based across segments: research services (chemistry, biology, translational science, clinical) and CDMO (small and large molecules).
- Capacity utilization improvements are underway in CDMO facilities in Bangalore, Mangalore, and Bayview (US), with early encouraging signs but still below expectations.
- Management is focused on diversifying the business to reduce reliance on single large products and accelerating pipeline fill and capacity utilization to drive mid-to-long-term growth.
2 more points from Syngene International Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Syngene invested approximately $9 million in CAPEX during Q3 FY26.
- Around 50% of CAPEX was for research services, including capability builds such as DMPK biology, ADC labs, and dedicated centers.
- Approximately 35% was spent in the CDMO business on a new commercial-scale facility for liquid-filled hard gelatin capsules, integration of the Bayview facility (US biologics), and modifications to Unit-3.
- Remaining CAPEX was directed toward digitization, automation, and common infrastructure.
- The Bayview biologics facility in the US has completed process and equipment validation, with hiring underway to support operations as planned.
2 more points from Syngene International Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It highlights ongoing efforts to build and strengthen the business pipeline across research services and CDMO, indicating a focus on increasing capacity utilization at facilities in Bangalore, Mangalore, and Bayview (US).
- Early encouraging signs of business traction and pipeline building are mentioned for both small and large molecule manufacturing operations.
- The company is working on diversifying its portfolio to reduce exposure to single large products and build multiple large client relationships.
2 more points from Syngene International Ltd's call on order book
Create a free account to keep reading this call
Syngene International Ltd — Quarterly revenue & net profit
Syngene International Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 917 | 944 | -2.9% | 911 | +0.7% |
| Operating profit (EBITDA) | 209 | 284 | -26.4% | 200 | +4.5% |
| Operating margin | 23% | 30% | -7 pp | 22% | +1 pp |
| Profit before tax | 28 | 181 | -84.5% | 85 | -67.1% |
| Net profit (PAT) | 15 | 131 | -88.5% | 67 | -77.6% |
| EPS (₹) | 0.37 | 3.26 | -88.7% | 1.67 | -77.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹833 Cr, net profit ₹32 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Syngene International's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality Care Ltd (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Syngene International Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Syngene International Ltd Q3 FY26 results?
Syngene expects the single large molecule product impact to continue through FY26 Q4 and into a couple of quarters in FY27 before it plays out. Syngene expects the single large molecule product impact to continue into FY27 but to play out over the next few quarters.
What is Syngene International Ltd share price analysis?
Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.
Is Syngene International Ltd planning capital expenditure?
Syngene invested approximately $9 million in CAPEX during Q3 FY26.
Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.